Empagliflozin and Metformin HCL | Boehringer Ingelheim | ||
5mg;500mg/1gm, 12.5mg;500mg/1gm, Tablet, Oral |
Less Than $1000 mn
|
||
Less Than 5
|
More Than 5
|
||
More Than 5
|
Less Than 5
|
||
None | None | ||
Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. | |||
Yes
|
SYNJARDY | Patent 1 | Patent 2 | Patent 3 | Patent 4 | Patent 5 |
---|---|---|---|---|---|
********* | ******* | *** ********* | ********* | ******* | ******* |
***** ****** | ******* | ******* | **** ** ** | ******* | *** ********* (***** ******) |
******* | ******* | **** *** | ******* | ******* | *** ********* (***** ******) |
Company | FTF Status / 180 days exclusivity | 30-Months stay | Current Litigation Status | Current Approval Status | Likelihood of launch |
---|---|---|---|---|---|
********* | *** \ ********* | *** *, **** | ******* | **** | ******* *** **** *** *** **** |
***** ****** | *** \ *** | *** *, **** | ******* ***** ****** ** ** | ******** ************ | ******* *** **** *** *** **** |
******* | *** \ *** | *** *, **** | ******* | **** | ******* *** **** *** *** **** |